India considers faster generic-drug study clearances and halved import-licence timelines
The government is considering allowing eligible drugmakers to begin domestic bioavailability-bioequivalence studies after regulator notification, rather than prior approval. It also proposes reducing import-licence processing for new-drug testing and reference products from 90 to 45 working days.
What happened
Government of India · India plans to let eligible drugmakers begin domestic BA-BE studies after notifying the regulator rather than awaiting approval,
Key facts
- BA-BE prior-intimation system to be extended from export-purpose studies to domestic generic-drug approvals
- Import licence processing timeline proposed to fall from 90 working days to 45 working days
- Rules 67, 68, 69 and 70 of the New Drugs and Clinical Trials Rules, 2019
Why this matters
Faster bioequivalence-study and import-licence processes could make Indian generic developers more attractive partners or acquisition targets for companies seeking quicker local product pipelines.
What to watch
- Publication of final notification, eligibility criteria and effective date for notification-based BA/BE study initiation.
- Whether the reform applies to all generics or excludes complex products, narrow-therapeutic-index drugs, biologics and higher-risk therapies.
- CDSCO guidance on documentation, inspection rights, suspension provisions and post-study reporting requirements.
- Actual median import-licence turnaround times after implementation versus the proposed 45 working days.
- CRO capacity utilization, BA/BE study pricing and recruitment timelines as sponsors bring forward programs.
- Announcements from leading Indian generic manufacturers regarding accelerated filings, launches or expanded domestic R&D pipelines.
- Prioritize BA/BE pipelines with high-volume off-patent opportunities and products dependent on imported reference standards.
- Increase capacity bookings at accredited domestic CROs and bioanalytical laboratories before demand tightens.
- Rework launch forecasts, working-capital plans and API procurement schedules around shorter expected development and import lead times.
- Use faster reference-product import processing to expand complex-generic and niche-therapy development programs.
- Strengthen pharmacovigilance, data-integrity and site-compliance controls, as accelerated pathways will likely bring closer post-notification scrutiny.